Fractional tumor burden refines prognostic stratification beyond MGMT status in glioblastoma after chemoradiotherapy

Background and Purpose. Following standard-of-care treatment for glioblastoma, response to chemoradiotherapy is difficult to evaluate because changes on postcontrast T1WI may represent either treatment effect or tumor progression, particularly in the early posttreatment period. Although O6-methylguanine DNA methyltransferase promoter methylation is prognostic and informs treatment response, outcomes among patients remain heterogeneous. We hypothesized that combining advanced physiologic imaging with methylation status would improve early prognostic stratification. Materials and Methods. In thi

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.